Skip to main content

Product Pipeline

Through the lens of hepatalin, Scimar has conceived four products designed to enhance human health and manage type 2 diabetes. Each product is at a different stage of development.

Doing Things Well

Our product pipeline is designed to do things well. We source our ingredients from the highest-quality suppliers. We include normally excluded groups from our clinical trials, such as women and Indigenous peoples, to ensure our data better reflects the real world. And we partner with third-party clinical trial agencies to ensure our results are unbiased.

A pouch-like package labelled

SciMar NuPa Test

Product description

NuPa Test is a diagnostic test meal designed to measure hepatalin production. The test will warn the onset of prediabetes and type 2 diabetes years earlier than the oral glucose tolerance test, the current standard for diagnosing type 2 diabetes. A NuPa Test prototype is going into Phase 2 clinical trials (Canada).

Patents

U.S., Canada, Australia, U.K., Germany, France
A spread of seven small sachets labelled

SciMar NuPa Daily

Product description

NuPa Daily is an antioxidant nutraceutical designed to boost metabolism, strengthen immunity, improve mood balance, and protect the liver’s production of hepatalin.

Patents

U.S.
A digital rendering of a pill bottle next to two pills are displayed. The pill bottle is labelled

SciMar NuPa Renew

Product description

NuPa Renew is a pharmaceutical which, when taken before a meal, will stimulate the healthy production of hepatalin and promote balanced nutrient partitioning. Scimar is preparing NuPa Renew for Phase 2B clinical trials.

Patents

U.S., Canada, China, Australia, U.K., Germany, France, Japan, New Zealand, Hong Kong
A digital rendering of a hypodermic needle and three small vials are displayed. The vials are labelled

Hepatalin-S

PRODUCT DESCRIPTION

Hepatalin-S is the synthetic version of hepatalin. We envision that this synthetic hormone will be used on its own, or in combination with insulin, to improve the health of people already living with late-stage diabetes.

Patents

U.S., Canada, Australia, U.K., Germany, France